LINAGLIPTIN (linagliptin) by Aurobindo Pharma is dipeptidyl peptidase 4 inhibitors [moa]. Approved for dipeptidyl peptidase 4 inhibitor [epc]. First approved in 2025.
Drug data last refreshed 21h ago
Dipeptidyl Peptidase 4 Inhibitors
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
The Bioequivalence Study of Linagliptin 5 mg Film-coated Tablet in Healthy Thai Volunteers
Real-world Study Comparing the Adherence and Effectiveness of Linagliptin vs. Acarbose
This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills
Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM
Real World Glycemic Effectiveness of Linagliptin
Worked on LINAGLIPTIN at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.